WT1基因在白血病患者中的表达及临床意义
Expression of Wilms' Tumor Gene(WT1) in Leukemia Patients and Its Clinical Significance
-
摘要: [摘要]目的 研究WT1基因在白血病患者中的表达及其临床意义.方法 运用RT-PCR方法检测 WT1基因在200例白血病患者中的表达.结果 急性髓细胞白血病(AML)和急性淋巴细胞白血病(ALL)WT1表达阳性率分别为79.2%(76/96)和57.1%(32/56).慢性粒细胞白血病(CML)慢性期WT1表达均阴性,急变期57.1%(8/14)表达阳性.WT1阳性患者化疗缓解率低于阴性患者(分别为55.7%和85.4%,P<0.05).结论 WT1在白血病患者中高表达,可作为临床评估预后、检测微小残留病(MRD)的标志.Abstract: [Abstract]Objective To evaluate the expression of WT1 gene in leukemia patients and its clinical implication.Method Nest RT-PCR technique was applied to examine WT1 gene expression in 200 patients with leukemia.Results The WT1 mRNA positive rates in acute myeloid leukemia and lymphoblastic leukemia were 79.2%(76/96)and 57.1%(32/56). In chronic myeloid leukemia,WT1 mRNA was undetectable in chronic phase; but was revealed in 8 of 14 patients at blast crisis(57.1%). The rate of remission in the patients positive for WT1 was lower than in those negative for WT1(55.7% vs 85.4%,P<0.005).Conclusion The WT1 is highly expressed in the majority of the patients with leukemia and thus is involved in human leukemogenesis. WT1 may be a new prognostic factor and a panleukemia marker for the detection of MRD.
点击查看大图
计量
- 文章访问数: 1908
- HTML全文浏览量: 642
- PDF下载量: 410
- 被引次数: 0